메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Ping An Ranks 47th on 2025 Fortune Global 500 List, Marking 16th Year on List

HONG KONG and SHANGHAI, July 30, 2025 -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) is #47 globally on the latest Fortune Global 500 list, up six places from 2024, with operating revenue of about USD158.63 billion. The Company, which ranked 9th among global financial enterprises, has been included in the Fortune Global 500 list for 16 consecutive years. Ping An continues to advance its technology-enabled "integrated finance + health and senior care" strategy, accelerating it
- 황정호 기자
- 2025-07-30 15:17
Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 30, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it will present Phase II clinical data on its next-generation, fully human heavy-chain-only anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), at the ESMO Congress 2025, taking place October 17-21, 2025, in Berlin, Germ
- 김갑성 기자
- 2025-07-30 08:01
Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025. An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025). Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/x4gytx8w/ Participants can register for the teleconference here: ht
- 황정호 기자
- 2025-07-30 07:00
Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, to possibly enable earlier creation and use of AV fistula Results to be presented at American Society of Nephrology (ASN) Annual Meeting in November SYDNEY and SAN ANTONIO, July 30, 2025 -- Vexev, an Australian-based medical device company advancing next-generation vascular imaging, and U.S. Renal Care, a leading provider of in-cente
- 김갑성 기자
- 2025-07-30 06:02
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other dementia. The guideline focuses on the use of blood-based biomarker tests by specialists to assess levels of Alzheimer's disease pathology in people with cognitive impairment. The Alzheimer's Association provides evidence-based resources to help clinicians identify the disease early and ensure patients receive the right treatment as quickly as possible. These and other planned guidelines
- 김갑성 기자
- 2025-07-30 02:44
Ping An Appoints AI Expert Ray Wang as Chief Technology Officer to Accelerate Comprehensive Digital Transformation

HONG KONG and SHANGHAI, July 29, 2025 -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) has announced the appointment of Mr. Ray Wang as the Group's Chief Technology Officer (CTO) and General Manager of Ping An Technology. The appointment of Ray Wang will significantly enhance the Company's research and development (R&D) and application capabilities in artificial intelligence (AI). His leadership is expected to drive the deep integration of Ping An's self-developed large language models and
- 황정호 기자
- 2025-07-29 22:12
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

[ 메디채널 김갑성 기자 ] NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a strategic collaboration with the German Center for Neurodegenerative Diseases (DZNE) to deploy its ultra-sensitive [ 메디채널 김갑성 기자 ] NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 in the Rhineland Study—one of the world's most comprehensive and innovative longitudinal aging cohorts,
- 김갑성 기자
- 2025-07-29 21:12
알라마 바이오사이언스, 독일 신경퇴행성질환센터(DZNE)와 파트너십 체결 - 라인란트 연구 코호트에서 대규모 단백질체 분석 연구 착수

[ 메디채널 김갑성 기자 ] NULISAseq™ CNS 질환 패널 120 및 염증 패널 250 활용 - 2만 3천 개의 종단 샘플에서 바이오마커 발굴 가속화 프리몬트, 캘리포니아, 2025년 7월 29일 -- 정밀 단백체학을 기반으로 질병의 조기 진단을 선도하고 있는 알라마 바이오사이언스(Alamar Biosciences)가 오늘 독일 신경퇴행성질환센터(German Center for Neurodegenerative Diseases, DZNE)와 전략적 협업을 발표했다. 이번 협약을 통해 알라마의 초고감도 [ 메디채널 김갑성 기자 ] NULISAseq™ CNS 질환 패널 120 및 염증 패널 250이 세계에서 가장 포괄적이고 혁신적인 종단 노화 코호트 중 하나인 라인란트 연구(Rhineland Study) 및 DZNE의 특정 임상 질환 코호트에 적용될 예정이다. 이 이니셔티브는 2만 3천 개의 혈장 샘플을 분석해 바이오마커 발굴을 가속화하고 건강한 노화 및 신경 퇴행에 대한 이해를 증진한다는 계획이다. DZNE의 인구 보건 과학 담당 이사이자 라인란트 연구의 수석 연구원인 모니크 브레텔러(Monique Bret
- 김갑성 기자
- 2025-07-29 21:12
Quasar Medical Unveils New Global Headquarters in Singapore

This move strategically enhances Quasar's ties to Singapore's MedTech ecosystem and facilitates closer collaboration with global partners SINGAPORE, July 29, 2025 -- Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced today the opening of its Global Headquarters in Singapore. This milestone marks the company's continued growth and reinforces its commitment to advancing medical innovation worldwide. Quasar has operated out of Hong Kong since its founding in 1988 and will continue to maintain comprehensive busin
- 김갑성 기자
- 2025-07-29 20:00
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress

PRINCETON, N.J. and TOKYO, July 29, 2025 -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T-c
- 김갑성 기자
- 2025-07-29 20:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-07_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 07일 19시 40분